Last reviewed · How we verify
SER120 750 ng
SER120 is a small molecule that targets the serotonin receptor.
SER120 is a small molecule that targets the serotonin receptor. Used for Major depressive disorder.
At a glance
| Generic name | SER120 750 ng |
|---|---|
| Sponsor | Serenity Pharmaceuticals, Inc. |
| Drug class | Serotonin receptor modulator |
| Target | 5-HT receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
It is believed to modulate serotonin signaling pathways, although the exact mechanism is not fully understood.
Approved indications
- Major depressive disorder
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia (PHASE3)
- Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4 (PHASE3)
- Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SER120 750 ng CI brief — competitive landscape report
- SER120 750 ng updates RSS · CI watch RSS
- Serenity Pharmaceuticals, Inc. portfolio CI